• Users Online: 129
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
   Table of Contents - Current issue
Coverpage
July-September 2020
Volume 14 | Issue 3
Page Nos. 61-82

Online since Thursday, September 17, 2020

Accessed 1,263 times.

PDF access policy
Journal allows immediate open access to content in HTML + PDF
View as eBookView issue as eBook
Access StatisticsIssue statistics
RSS FeedRSS
Hide all abstracts  Show selected abstracts  Export selected to  Add to my list
ORIGINAL ARTICLES  

Correlation between psoriasis and ZIP2 and ZIP3 Zinc transporters p. 61
Sevilay Kilic, Hilal Müserref Şehitoğlu
DOI:10.4103/TJD.TJD_29_20  
Aims: Psoriasis is a chronic, inflammatory, hyperproliferative skin disease with etiopathogenesis not fully understood. The zinc transporter ZIP2 is associated with keratinocyte differentiation, whereas ZIP3 is associated with T-lymphocyte maturation. In our study, we aimed to show the correlation between psoriasis and ZIP2 and ZIP3 zinc transporters in psoriasis patients. Subjects and Methods: The patient group in the study included 60 patients aged with psoriasis vulgaris and a control group of 60 healthy adults. The levels of ZIP2 (SLC39A2) and ZIP3 (SLC39A3) zinc transporters were determined with the ELISA method. Results were compared with control group values and statistically assessed. Results: When the ZIP2 and ZIP3 levels are compared in controls and psoriasis patients, the levels were observed to significantly increase compared to controls (P < 0.05). When compared to the control group, the results appeared to be statistically significant (P < 0.05). Conclusions: With etiopathogenesis not fully known, there may be an important relationship between psoriasis development and ZIP2 (SLC39A2) and ZIP3 (SLC39A3) zinc transporters in psoriasis vulgaris patients. This situation may be an important result for understanding how the disease develops and in creating new approaches in terms of treatment for this disease without full cure available.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta

Hepatitis B Virus Reactivation in Patients with Psoriasis on Biologic Therapies: A Retrospective Study p. 65
Sinan Ozcelik, Fatma Arzu Kılı
DOI:10.4103/TJD.TJD_42_20  
Background: There are limited data on the safety of biological therapies in psoriasis patients with hepatitis B virus (HBV) infection in the literature, and are still ongoing controversies about HBV reactivation in patients treated with biologics for psoriasis. Aims: This was aimed to investigate the demographic, clinical, and laboratory characteristics of the patients with HBV seropositive receiving biological treatment for psoriasis. Study Design: This was a retrospective observational study. Materials and Methods: Ninety-seven patients with psoriasis treated with biologics in the outpatient clinic were evaluated retrospectively. Of these, 16 patients with HBV seropositive were included in the study. Patients with positive HBV serology were divided into three groups as chronic HBV infection, past HBV infection, and isolated core antibody positivity (HBV core-specific antibody [HBcAb]). The demographic, clinical, and laboratory characteristics of the patients were obtained from the records. Results: Of the patients, 5 patients were female (31.2%), and 11 were male (68.8%). The mean age of the patients was 55.81 ± 11.05. Thirteen of the patients had past HBV infection, three had isolated HBcAb positive. Infliximab (n = 13) was the most common biologic agent used, followed by adalimumab (n = 6), secukinumab (n = 4), ustekinumab (n = 2), and etanercept (n = 2). The mean duration of treatment was 3.59 ± 2.76 years. The HBV reactivation occurred in only one patient with past HBV infection receiving infliximab (6.2%). Conclusion: It remains unclear how exactly the biologic drugs for psoriasis impact viral reactivation. For the safe use of biological agents in psoriasis patients with HBV seropositive, screening tests must be performed with a triple serology, including HBV surface antigen, HBV surface-specific antibody, and HBcAb. The patients who have positive HBV serology must be monitored closely with reactivation markers and receive antiviral prophylaxis if they are at moderate-to-high risk of HBV reactivation.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta

The effect of coenzyme Q10 on serum glutathione peroxidase levels and severity of acne vulgaris p. 71
Maria Leleury, Diah Adriani, Retno Indar Widayati, Kabulrachman , Asih Budiastuti, Muslimin
DOI:10.4103/TJD.TJD_51_20  
Objective: The objective of the study was to study the effect of coenzyme Q10 (CoQ10) supplementation on serum glutathione peroxidase (GSH-Px) levels and the severity of acne vulgaris (AV). Methods: A double-blind randomized controlled trial was carried out on 36 patients with AV classified according to severity. These patients were randomly divided into two groups (treatment group = 18 patients treated with tretinoin 0.025% cream and once-daily supplementation with a CoQ10 100 mg tablet; placebo group = 18 patients treated with tretinoin 0.025% cream and a once-daily placebo tablet). Blood samples were taken from a vein and examined by enzyme-linked immunosorbent assay. The study period was 8 weeks. Response to treatment was determined based on serum GSH-Px level and AV severity. The study used a pre- and post-test design for the two groups. The data were processed with SPSS for Windows version 25. Results: Administration of CoQ10 to AV significantly improved the severity of AV after 8 weeks compared to a placebo (P = 0.008). Serum GSH-Px levels after treatment with CoQ10 increase higher in the study than control group, but the statistical test result showed not significant in the study group (P = 0.3) and also control group (P = 0.07). Conclusion: CoQ10 supplementation may increase serum GSH-Px levels and improve the severity of AV, but there was no relationship between serum GSH-Px levels and the severity of AV.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta
CASE REPORT Top

Psoriasis presenting as targetoid lesions: First of its kind p. 76
Pallavi Goyal, Surabhi Dayal, Priyadarshini Sahu
DOI:10.4103/TJD.TJD_41_20  
Psoriasis is a common chronic inflammatory and proliferative condition of the skin and its presentation as targetoid lesions has not been described. A 29-year-old male came to the outpatient department with multiple red color elevated skin lesions over the forehead and trunk for the past 10 days. Multiple targetoid lesions of size 2 cm × 2 cm to 5 cm × 4 cm having central edematous crusted zone and the peripheral zone of erythema with irregular to well-defined margins present almost all over the body. Differential diagnosis included psoriasis, erythema multiforme, pemphigus erythematosus, and reiter's disease. The biopsy confirmed the diagnosis of psoriasis. The patient was started on injection methotrexate and responded well.
[ABSTRACT]  [HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta
LETTERS TO THE EDITOR Top

A case of generalized granuloma annulare with diabetes mellitus: Regressed with antidiabetic therapy p. 79
Hari Pathave, Vaibhav Barve, Hanamant Gadade, Chitra Nayak
DOI:10.4103/TJD.TJD_43_20  
[HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta

Pinch purpura: A clinical clue for primary systemic amyloidosis p. 81
Ashwini R Mahesh, T Satyaprakash, Deepak Joshi, Gandikota Raghurama Rao, Kollipara Haritha, A Prasad Chowdary
DOI:10.4103/TJD.TJD_62_20  
[HTML Full text]  [PDF]  [Mobile Full text]  [EPub]  [Sword Plugin for Repository]Beta